

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-75. (Cancelled)
76. (New) A method for treating a tumor, comprising administering indinavir at a daily dose of 1200 mg to a human subject having a tumor.
77. (New) A method for blocking cell migration or invasion, comprising administering indinavir at a daily dose of 1200 mg to a human subject in need of said blocking.
78. (New) The method of claim 77, wherein said blocking is of neoplastic cell migration or invasion.
79. (New) The method of claim 76 or 77, wherein said human subject is not infected with HIV.
80. (New) The method of claim 76 or 77, further comprising administering to said human subject nelfinavir.
81. (New) The method of claim 76, wherein the tumor is Kaposi's sarcoma.
82. (New) The method of claim 76, wherein the tumor is a benign tumor of soft tissue, cartilage, bone or blood.
83. (New) The method of claim 76, wherein the tumor is a malignant tumor of soft tissue, cartilage, bone or blood.
84. (New) The method of claim 76 or 77, further comprising administering to said human subject an anti-inflammatory, anti-angiogenic or anti-tumor drug.
85. (New) The method of claim 76 or 77, wherein said administering of the indinavir is orally, intravenously, intramuscularly, subcutaneously, intradermally, intraperitoneally, intrathecally, intrapleurally, intrauterine, transmucosally, rectally, vaginally, intralesionally or percutaneously.

Appl. No. 10/549,958
Attorney Docket No. 11340-007-999
Amdt. dated Feb. 8, 2008
Reply to Office Action mailed Jan. 9, 2008

86. (New) The method of claim 76 or 77, wherein said administering of the indinavir is orally.